Galectin expression profiling identifies galectin-1 and Galectin-9Δ5 as prognostic factors in stage I/II non-small cell lung cancer.

Approximately 30-40% of the patients with early stage non-small cell lung cancer (NSCLC) will present with recurrent disease within two years of resection. Here, we performed extensive galectin expression profiling in a retrospective study using frozen and paraffin embedded tumor tissues from 87 sta...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Iris A Schulkens, Roy Heusschen, Vivian van den Boogaart, Robert-Jan van Suylen, Anne-Marie C Dingemans, Arjan W Griffioen, Victor L Thijssen
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/67e46d41674a4581ba2c9e7c25de27bb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:67e46d41674a4581ba2c9e7c25de27bb
record_format	dspace
spelling	oai:doaj.org-article:67e46d41674a4581ba2c9e7c25de27bb2021-11-25T05:59:07ZGalectin expression profiling identifies galectin-1 and Galectin-9Δ5 as prognostic factors in stage I/II non-small cell lung cancer.1932-620310.1371/journal.pone.0107988https://doaj.org/article/67e46d41674a4581ba2c9e7c25de27bb2014-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0107988https://doaj.org/toc/1932-6203Approximately 30-40% of the patients with early stage non-small cell lung cancer (NSCLC) will present with recurrent disease within two years of resection. Here, we performed extensive galectin expression profiling in a retrospective study using frozen and paraffin embedded tumor tissues from 87 stage I/II NSCLC patients. Our data show that galectin mRNA expression in NSCLC is confined to galectin-1, -3, -4, -7, -8, and -9. Next to stage, univariable Cox regression analysis identified galectin-1, galectin-9FL and galectin-9Δ5 as possible prognostic markers. Kaplan-Meier survival estimates revealed that overall survival was significantly shorter in patients that express galectin-1 above median levels, i.e., 23.0 (2.9-43.1) vs. 59.9 (47.7-72.1) months (p = 0.020) as well as in patients that express galectin-9Δ5 or galectin-9FL below the median, resp. 59.9 (41.9-75.9) vs. 32.8 (8.7-56.9) months (p = 0.014) or 23.2 (-0.4-46.8) vs. 58.9 (42.9-74.9) months (p = 0.042). All three galectins were also prognostic for disease free survival. Multivariable Cox regression analysis showed that for OS, the most significant prognostic model included stage, age, gal-1 and gal-9Δ5 while the model for DFS included stage, age and gal-9Δ5. In conclusion, the current study confirms the prognostic value of galectin-1 and identifies galectin-9Δ5 as novel potential prognostic markers in early stage NSCLC. These findings could help to identify early stage NSCLC patients that might benefit most from adjuvant chemotherapy.Iris A SchulkensRoy HeusschenVivian van den BoogaartRobert-Jan van SuylenAnne-Marie C DingemansArjan W GriffioenVictor L ThijssenPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 9, p e107988 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Iris A Schulkens Roy Heusschen Vivian van den Boogaart Robert-Jan van Suylen Anne-Marie C Dingemans Arjan W Griffioen Victor L Thijssen Galectin expression profiling identifies galectin-1 and Galectin-9Δ5 as prognostic factors in stage I/II non-small cell lung cancer.
description	Approximately 30-40% of the patients with early stage non-small cell lung cancer (NSCLC) will present with recurrent disease within two years of resection. Here, we performed extensive galectin expression profiling in a retrospective study using frozen and paraffin embedded tumor tissues from 87 stage I/II NSCLC patients. Our data show that galectin mRNA expression in NSCLC is confined to galectin-1, -3, -4, -7, -8, and -9. Next to stage, univariable Cox regression analysis identified galectin-1, galectin-9FL and galectin-9Δ5 as possible prognostic markers. Kaplan-Meier survival estimates revealed that overall survival was significantly shorter in patients that express galectin-1 above median levels, i.e., 23.0 (2.9-43.1) vs. 59.9 (47.7-72.1) months (p = 0.020) as well as in patients that express galectin-9Δ5 or galectin-9FL below the median, resp. 59.9 (41.9-75.9) vs. 32.8 (8.7-56.9) months (p = 0.014) or 23.2 (-0.4-46.8) vs. 58.9 (42.9-74.9) months (p = 0.042). All three galectins were also prognostic for disease free survival. Multivariable Cox regression analysis showed that for OS, the most significant prognostic model included stage, age, gal-1 and gal-9Δ5 while the model for DFS included stage, age and gal-9Δ5. In conclusion, the current study confirms the prognostic value of galectin-1 and identifies galectin-9Δ5 as novel potential prognostic markers in early stage NSCLC. These findings could help to identify early stage NSCLC patients that might benefit most from adjuvant chemotherapy.
format	article
author	Iris A Schulkens Roy Heusschen Vivian van den Boogaart Robert-Jan van Suylen Anne-Marie C Dingemans Arjan W Griffioen Victor L Thijssen
author_facet	Iris A Schulkens Roy Heusschen Vivian van den Boogaart Robert-Jan van Suylen Anne-Marie C Dingemans Arjan W Griffioen Victor L Thijssen
author_sort	Iris A Schulkens
title	Galectin expression profiling identifies galectin-1 and Galectin-9Δ5 as prognostic factors in stage I/II non-small cell lung cancer.
title_short	Galectin expression profiling identifies galectin-1 and Galectin-9Δ5 as prognostic factors in stage I/II non-small cell lung cancer.
title_full	Galectin expression profiling identifies galectin-1 and Galectin-9Δ5 as prognostic factors in stage I/II non-small cell lung cancer.
title_fullStr	Galectin expression profiling identifies galectin-1 and Galectin-9Δ5 as prognostic factors in stage I/II non-small cell lung cancer.
title_full_unstemmed	Galectin expression profiling identifies galectin-1 and Galectin-9Δ5 as prognostic factors in stage I/II non-small cell lung cancer.
title_sort	galectin expression profiling identifies galectin-1 and galectin-9δ5 as prognostic factors in stage i/ii non-small cell lung cancer.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/67e46d41674a4581ba2c9e7c25de27bb
work_keys_str_mv	AT irisaschulkens galectinexpressionprofilingidentifiesgalectin1andgalectin9d5asprognosticfactorsinstageiiinonsmallcelllungcancer AT royheusschen galectinexpressionprofilingidentifiesgalectin1andgalectin9d5asprognosticfactorsinstageiiinonsmallcelllungcancer AT vivianvandenboogaart galectinexpressionprofilingidentifiesgalectin1andgalectin9d5asprognosticfactorsinstageiiinonsmallcelllungcancer AT robertjanvansuylen galectinexpressionprofilingidentifiesgalectin1andgalectin9d5asprognosticfactorsinstageiiinonsmallcelllungcancer AT annemariecdingemans galectinexpressionprofilingidentifiesgalectin1andgalectin9d5asprognosticfactorsinstageiiinonsmallcelllungcancer AT arjanwgriffioen galectinexpressionprofilingidentifiesgalectin1andgalectin9d5asprognosticfactorsinstageiiinonsmallcelllungcancer AT victorlthijssen galectinexpressionprofilingidentifiesgalectin1andgalectin9d5asprognosticfactorsinstageiiinonsmallcelllungcancer
_version_	1718414344315731968

Galectin expression profiling identifies galectin-1 and Galectin-9Δ5 as prognostic factors in stage I/II non-small cell lung cancer.

Ejemplares similares